^
    6d
    SKylaRk: KRDI in Transplant-Eligible MM (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Mar 2026 --> Dec 2026
    Trial completion date
    |
    lenalidomide • carfilzomib • Sarclisa (isatuximab-irfc)
    7d
    Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Mar 2031 --> May 2033 | Trial primary completion date: Mar 2026 --> May 2033
    Trial completion date • Trial primary completion date
    |
    lenalidomide • dexamethasone • Sarclisa (isatuximab-irfc)
    13d
    EMN24: A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenalidomide-Dexamethasone in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL) (2024-513422-38-00)
    P2/3, N=302, Active, not recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc)
    14d
    NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Elvira Umyarova | Trial primary completion date: Aug 2026 --> May 2026
    Trial primary completion date
    |
    SLAMF7 (SLAM Family Member 7)
    |
    cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
    18d
    Isa Iber VD: A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant (clinicaltrials.gov)
    P1/2, N=88, Not yet recruiting, Dana-Farber Cancer Institute
    New P1/2 trial
    |
    bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • iberdomide (CC-220)
    20d
    CONQUISTADOR: Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=220, Not yet recruiting, Universitätsklinikum Hamburg-Eppendorf
    New P1/2 trial
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • etentamig intravenous (ABBV-383 IV)
    23d
    Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective. (PubMed, Front Immunol)
    CD38_targeting monoclonal antibodies (mAbs), including daratumumab (DARA) and isatuximab (ISA), exert antitumor activity through direct cytotoxicity and immune modulation; however, resistance to these agents remains a major clinical challenge. This sustained ADO production may contribute to a tolerogenic BM niche that promotes immune evasion and therapeutic resistance. These results support the rationale for combining CD38_directed antibodies with agents targeting adenosinergic signaling to enhance antitumor immunity and improve clinical outcomes in MM.
    Journal • IO biomarker
    |
    CD73 (5'-Nucleotidase Ecto)
    |
    Darzalex (daratumumab) • Sarclisa (isatuximab-irfc)
    26d
    CM336-RI: CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment (clinicaltrials.gov)
    P2, N=20, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Sarclisa (isatuximab-irfc)
    26d
    Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=300, Recruiting, Multiple Myeloma Research Consortium | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    SDC1 (Syndecan 1)
    |
    TP53 mutation
    |
    clonoSEQ®
    |
    Sarclisa (isatuximab-irfc) • Lynozyfic (linvoseltamab-gcpt)
    1m
    DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1/2, N=208, Active, not recruiting, GlaxoSmithKline | Phase classification: P2 --> P1/2
    Phase classification
    |
    lenalidomide • Jemperli (dostarlimab-gxly) • dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998
    1m
    IMROZ: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=475, Active, not recruiting, Sanofi | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
    1m
    ICING: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy (clinicaltrials.gov)
    P2, N=37, Completed, Won Seog Kim | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Libtayo (cemiplimab-rwlc) • Sarclisa (isatuximab-irfc)